Latest JUPITER trial Stories
Rolling back suggestions from previous studies, a Johns Hopkins study of 950 healthy men and women has shown that taking daily doses of a cholesterol-lowering statin medication to protect coronary arteries and ward off heart attack or stroke may not be needed for everyone.
Average C-reactive protein (CRP) values vary in diverse populations â€” possibly impacting how doctors estimate cardiovascular risk and determine statin treatment.
A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke.
DUBLIN, Ireland and MYSTIC, Conn., Aug.
The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol.
A meta-analysis of previously published studies finds no evidence that statins are associated with a reduced risk of death among individuals at risk for but with no history of cardiovascular disease.
On Monday, researchers said they did not find evidence that cholesterol-reducing drugs can help extend the life of patients at risk of heart disease.
C-reactive protein (CRP) is used to assess disease activity in diverse inflammatory disorders including inflammatory bowel disease (IBD).
Prognostic markers provide tools for discriminating between groups of patients who are at different risks of a particular outcome, and therefore should help clinicians to manage disease.
New study finds post-operative statin use decreases the need for revision surgery.